Storys aus New York
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- 2mehr
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognostic risk groups and ...
mehrAbstracts highlight data on BAVENCIO as a monotherapy and in combination in multiple advanced cancers
Not intended for US, Canada and UK-based media Darmstadt, Germany, and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the presentation of multiple analyses from the JAVELIN clinical development program assessing BAVENCIO® (avelumab) alone or as part of combination regimens for the ...
mehrCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
mehrCaisse de dépôt et placement du Québec
CREO and CDPQ Announce Partnership to Invest in Sustainable Economy
Montreal and New York (ots/PRNewswire) - The CREO Family Office Syndicate (CREO), a not-for-profit global network of family offices headquartered in New York City, and Caisse de dépôt et placement du Québec (CDPQ), a leading long-term institutional investor, today announced a new partnership to foster more capital into climate investments by creating new opportunities, sharing expertise and exercising stronger climate ...
mehrMerck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
mehrPivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...
mehrFDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...
mehrMerck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...
mehrMerck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...
mehrTravelsify Raises EUR5 Million in New Funding Round and Launches Brand DNA AI Analytics for Hotels and Restaurants
New York and Luxembourg (ots/PRNewswire) - New Funding Round, Led By AccorHotels, To Accelerate The Development Of Services Leveraging Travelsify's Hotel DNA(TM) and Restaurant DNA(TM) AI Technology Travelsify (http://www.travelsify.com/), the world's first Travel & Lifestyle Product DNA platform, today announced ...
mehrBAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
mehrWorld Innovation Summit for Education (WISE)
The World Innovation Summit for Education (WISE) to Host Global Education Forum as Part of the United Nations' Global Goals Week, in NYC
New York (ots/PRNewswire) - The World Innovation Summit for Education (WISE) (https://www.wise-qatar.org/), an initiative of Qatar Foundation, will be holding a one-day forum, on September 22nd, as part of the Global Goals Week, during the United Nations General Assembly. The event will take place at the Altman ...
mehrMerck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose ...
mehrFDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - - Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer - Renal cell carcinoma, the most common form of kidney cancer, has a poor prognosis in advanced stage[1],[2] - Javelin Renal clinical development program is ongoing, including Phase III ...
mehrScotiabank to Partner with Two Israeli Technology Leaders to Accelerate its Digital Transformation
Toronto and New York (ots/PRNewswire) - Scotiabank announced today partnerships with two prominent Israeli technology leaders, Viola Group and Team8. These partnerships further establish Scotiabank as a leader in the global innovation ecosystem and will help accelerate its development of technology capabilities, ...
mehrMerck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoint of superior overall survival ...
mehrBavencio (avelumab) Approved for Merkel Cell Carcinoma in Japan
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
mehrEuropean Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
mehrBMO Capital Markets to Donate C$1.6 Million Following Equity Through Education Trading Day
Toronto, New York and London (ots/PRNewswire) - - Annual initiative has raised C$19.5 million since 2005, supporting more than 3,000 students - Program donates a day's worth of trading commissions generated by BMO Capital Markets in Canada, the U.S. and Europe BMO Capital Markets, the investment and corporate banking arm of BMO Financial Group (NYSE:BMO)(TSX:BMO), ...
mehrEMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - If approved, avelumab could be the first immunotherapy treatment indicated for this rare and aggressive skin cancer in the EU - Decision by the EC is expected in the third quarter of 2017 Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for ...
mehrHSH Prince Albert II of Monaco Establishes Monaco Explorations: A Three-year Campaign of Scientific Explorations at Sea
New York (ots/PRNewswire) - The transoceanic exploration vessel, Yersin, will depart from Monaco July 2017 and return Summer 2020. The vessel will navigate during three years the globe with the Monaco Explorations team alongside scientific and media teams, and will visit nine areas to conduct scientific research in ...
mehrMerck and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - A total of 13 abstracts across seven hard-to-treat cancers highlight the progress of avelumab as a monotherapy and potential novel combination treatment option - New data in metastatic Merkel cell carcinoma and ...
mehrFDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Darmstadt, Germany, and New York (ots/PRNewswire) - - Second approval for BAVENCIO in less than two months - Advanced urothelial carcinoma is an aggressive disease with a high rate of recurrence Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection for the treatment of patients with ...
mehrFDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - Only FDA-approved treatment for metastatic Merkel cell carcinoma, a rare and aggressive skin cancer - First indication for BAVENCIO, a human anti-PD-L1 antibody Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and ...
mehrFDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US and UK-based media - Second Biologics License Application accepted by the FDA for avelumab - Prognosis for urothelial carcinoma is currently poor, particularly when the disease has metastasized Merck and Pfizer Inc. today announced that the US ...
mehrMindshare Ends 2016 With Major Awards Across the World
London, New York, and Singapore (ots/PRNewswire) - Mindshare (http://www.mindshareworld.com), the global media agency network that is part of WPP (http://wpp.com) , has ended the year with the top awards across the most respected awards ceremonies globally. (Logo: http://photos.prnewswire.com/prnh/20151123/290080LOGO ) The agency's 2016 roll call of success includes: - Glass Lions Grand Prix ...
mehrFDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved by the FDA, avelumab, an investigational immunotherapy, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma (MCC) - Avelumab has previously received FDA Breakthrough Therapy and Fast ...
mehrEuropean Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved, avelumab, an investigational anti-PD-L1 IgG1, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma - The Marketing Authorization Application is based on Phase II data from the ...
mehrNow Open: Arc'teryx Veilance's First-Ever Concept Store in New York City
New York (ots/PRNewswire) - Technical Apparel Solutions for New York Weather Arc'teryx Veilance has partnered with renowned design firm Snarkitecture to bring a unique concept store experience to New York City. The bespoke space opened to the public today, October 28th, 2016 and will exist until January 8th, 2017. For discerning men, Arc'teryx Veilance is the vehicle ...
mehr